CATX vs. PLSE, INMD, MDXG, KMTS, SIBN, IRMD, CBLL, EMBC, BBNX, and AVNS
Should you be buying Perspective Therapeutics stock or one of its competitors? The main competitors of Perspective Therapeutics include Pulse Biosciences (PLSE), InMode (INMD), MiMedx Group (MDXG), Kestra Medical Technologies (KMTS), SiBone (SIBN), iRadimed (IRMD), CeriBell (CBLL), Embecta (EMBC), Beta Bionics (BBNX), and AVANOS MEDICAL (AVNS). These companies are all part of the "medical equipment" industry.
Perspective Therapeutics vs. Its Competitors
Perspective Therapeutics (NYSE:CATX) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.
In the previous week, Pulse Biosciences had 6 more articles in the media than Perspective Therapeutics. MarketBeat recorded 7 mentions for Pulse Biosciences and 1 mentions for Perspective Therapeutics. Pulse Biosciences' average media sentiment score of 0.41 beat Perspective Therapeutics' score of 0.00 indicating that Pulse Biosciences is being referred to more favorably in the news media.
Perspective Therapeutics currently has a consensus price target of $12.56, suggesting a potential upside of 215.47%. Pulse Biosciences has a consensus price target of $22.00, suggesting a potential upside of 37.24%. Given Perspective Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Perspective Therapeutics is more favorable than Pulse Biosciences.
54.7% of Perspective Therapeutics shares are held by institutional investors. Comparatively, 76.9% of Pulse Biosciences shares are held by institutional investors. 3.7% of Perspective Therapeutics shares are held by company insiders. Comparatively, 71.5% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Pulse Biosciences has a net margin of 0.00% compared to Perspective Therapeutics' net margin of -4,096.66%. Perspective Therapeutics' return on equity of -27.40% beat Pulse Biosciences' return on equity.
Perspective Therapeutics has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500.
Summary
Perspective Therapeutics beats Pulse Biosciences on 7 of the 13 factors compared between the two stocks.
Get Perspective Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CATX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Perspective Therapeutics Competitors List
Related Companies and Tools
This page (NYSE:CATX) was last updated on 7/12/2025 by MarketBeat.com Staff
Free CATX Stock Alerts